Management and outcome in invasive and locally advanced bladder cancer

ESU Course 23

**Location:** Room 21 (ICM, Level 2)

**Chair:** B. Malavaud, Toulouse (FR)

**Aims and objectives of this presentation**

MIBC is a multifaceted entity where one size no longer fits all, supporting the development of personalized and, in selected cases, organ-preserving strategies. Are the advances in imaging, molecular biology, conservative surgery, medical oncology and radiotherapy strong enough to shift the current pre-eminence of the ablative approach toward a more integrated and conservative perspective? If yes, what are the ideal candidates?

- One size does not fit all and urologists are central to the development of personalized treatment in MIBC
- Patients selection is critical and based on advances in imaging, resection techniques and pathology
- Organ preservation is feasible in a significant proportion of patients
- Radical cystectomy and pre-emptive chemotherapy are essential to optimize results in aggressive conditions.

12:00 - 14:00

**Cystectomy in the management of bladder invasive and locally advanced bladder cancer**

M. Burger, Regensburg (DE)

12:00 - 14:00

**Case discussion on cystectomy in the management of bladder invasive and locally advanced bladder cancer**

B. Malavaud, Toulouse (FR)

12:00 - 14:00

**Bladder sparing approaches to muscle invasive bladder cancer**

M. Burger, Regensburg (DE)

12:00 - 14:00

**Case discussion on bladder sparing approaches to muscle invasive bladder cancer**

B. Malavaud, Toulouse (FR)

12:00 - 14:00

**Cytotoxic chemotherapy in bladder cancer: Neoadjuvant and adjuvant setting and treatment of metastatic disease**

B. Malavaud, Toulouse (FR)